Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

BPC-157 vs ARA-290 (cibinetide)

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Verdict: favors ARA-290 (cibinetide)

ARA-290 has much stronger evidence: four small placebo controlled human trials show it improved neuropathy symptoms and regrew corneal nerve fibers in sarcoidosis and type 2 diabetes. BPC-157 has no controlled human trial and rests on rodent healing studies. Their legal paths differ: ARA-290 is an investigational drug with no federal basis to be compounded, while BPC-157, which is not FDA approved or on the 503A bulks list, is one of six peptides covered by HHS's October 28, 2026 draft enforcement discretion policy for single-ingredient compounding on a patient-specific prescription. The draft is not binding and does not change BPC-157's evidence grade.

Verified: Verified Oct 28, 2026
ARA-290 (cibinetide)
Favored
Full ARA-290 (cibinetide) record
BPC-157 oralSponsoredFrom Bodybuilding Peptides

Which is better, BPC-157 or ARA-290 (cibinetide)?

On evidence grade, ARA-290 wins clearly: it is graded human RCT from phase 2 trials (for example, 64 patients in a phase 2b trial with a significant increase in corneal nerve fiber area), while BPC-157 is animal only. The trials are small, short, and developer sponsored, and ARA-290 is available only in clinical trials. BPC-157 is not on the 503A bulks list and is covered only by HHS's draft enforcement discretion policy (FDA's drug center recommended against listing; the advisory committee voted in favor, per HHS's Appendix B), and it has no human proof, so ARA-290 is the better supported peptide even though it is harder to obtain lawfully. [1] [2] [3] [4] [5] [6] [15]

How do BPC-157 and ARA-290 (cibinetide) compare?

BPC-157 and ARA-290 (cibinetide) compared by dimension
DimensionBPC-157ARA-290 (cibinetide)Favored
What it is [7] [8]Synthetic 15 amino acid fragment of a gastric protein (body protection compound).Investigational 11 amino acid peptide copying helix B of erythropoietin, engineered to activate the innate repair receptor without raising red blood cells.
Evidence grade [1] [2] [3] [4] [9] [14]Animal only. No controlled human trial; three small uncontrolled pilot reports from one clinic.Human RCT. Four small phase 2 placebo controlled trials of 4 weeks or 28 days.
Main use studied [1] [3] [7] [10]Tendon, ligament, muscle, and gut healing in rodents.Small fiber neuropathy in sarcoidosis and painful neuropathy in type 2 diabetes in humans.
Key results [1] [2] [3] [7] [10]Faster rat Achilles tendon healing; healing of NSAID ulcers and fistulas in rodents.Neuropathy screening score improved 11.5 vs 2.9 points with placebo in 22 patients; corneal nerve fiber area rose significantly in a 64 patient phase 2b trial; HbA1c and neuropathic pain improved in type 2 diabetes.
Mechanism [8] [11]Growth factor receptor upregulation, nitric oxide modulation, and angiogenesis in animal models.Binds only the tissue protective innate repair receptor (erythropoietin receptor plus beta common receptor), avoiding the red cell, clotting, and blood pressure effects of erythropoietin.
Human safety data [1] [2] [4] [14]None systematic. Three small uncontrolled pilot reports (about 30 people) reported no adverse events; anecdotal injection site reactions.No safety concerns in 28 day trials and no rise in hemoglobin; long term safety unknown.
FDA and compounding status [5] [6] [15] [16]Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous, intramuscular, oral, or topical) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B).Investigational, not approved anywhere; not a component of an approved drug and not on the bulks list, so it has no federal basis to be compounded. Access only inside a clinical trial.
Routes in the literature [1] [2] [4] [14]Not established in humans; rodent studies used injection, drinking water, or topical application, and the human pilot reports used injections.Subcutaneous injection in the main phase 2 trials and intravenous infusion in the pilot trial. No lawful product exists outside a trial.
WADA status [12] [13]Prohibited at all times under S0 (non-approved substances).Prohibited under S0 as a non-approved substance; as an erythropoietin derived peptide it is also relevant to S2.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

BPC-157 and ARA-290 (cibinetide): grade, status, and cost
AttributeBPC-157ARA-290 (cibinetide)
ClassSynthetic gastric pentadecapeptide (15 amino acids), fragment of body protection compoundInvestigational 11 amino acid peptide derived from the helix B surface of erythropoietin, engineered to activate the innate repair receptor without stimulating red blood cell production
What it isA 15 amino acid peptide with strong animal healing data, no randomized human trial in PubMed, and a draft HHS compounding policy from October 2026.Erythropoietin derived peptide with small placebo controlled trials in sarcoidosis and diabetic neuropathy; investigational, not approved, WADA prohibited.
EvidenceEvidence: Animal-only evidenceEvidence: Human RCT evidence
FDA statusRegulatory: HHS interim policy (draft)Regulatory: Not eligible for compounding
CompoundingBPC-157 is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157 when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous, intramuscular, oral, or topical), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. Oral forms also need documentation that the formulation is adequately absorbed by mouth in humans. The draft policy is not an FDA approval, does not add BPC-157 to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.Investigational drug that has completed phase 2 trials but is not approved by FDA or any other regulator as of the last verification date. Because cibinetide is not a component of an approved drug, has no USP monograph, and is not on the 503A bulks list, a 503A pharmacy has no federal basis to compound it, and it is not eligible for 503B outsourcing. Products sold online as ARA-290 for human use are unapproved drugs.
WADAWADA: WADA prohibitedWADA: WADA prohibited
RoutesSubcutaneous injection (as sold), Oral capsule (as sold), Intraperitoneal, oral in water, and topical (animal studies)Subcutaneous injection once daily (phase 2 trials), Intravenous infusion (early pilot trial)
Typical costNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient BPC-157 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Last verified

Has BPC-157 been tested directly against ARA-290 (cibinetide)?

No published trial has compared BPC-157 and ARA-290 (cibinetide) directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do BPC-157 and ARA-290 (cibinetide) cost?

Typical cost of BPC-157 and ARA-290 (cibinetide)
DimensionBPC-157ARA-290 (cibinetide)
Typical costNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient BPC-157 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Price detailBPC-157 price by channelPrice index in progress

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the BPC-157 page and the ARA-290 (cibinetide) page.

Frequently asked questions

Which has better human evidence, BPC-157 or ARA-290?

ARA-290. It has four small placebo controlled trials in people with neuropathy, including a 64 patient phase 2b trial showing corneal nerve regrowth. BPC-157 has no controlled human trial, only three small uncontrolled pilot reports from one clinic. [1] [2] [4] [14]

Can I get ARA-290 from a compounding pharmacy?

No. Cibinetide is investigational, is not a component of an approved drug, and is not on the 503A bulks list, so neither 503A pharmacies nor 503B outsourcing facilities can lawfully make it. The only lawful access is a registered clinical trial. [5]

Does ARA-290 raise red blood cells like EPO?

No. It was designed to bind only the tissue repair receptor and did not raise hemoglobin or hematocrit in trials. [2] [8]

Is either one useful for tendon injuries?

Neither has human tendon data. BPC-157 has rodent tendon studies; ARA-290 was studied for nerve damage, not tendons. [1] [10]

Are BPC-157 and ARA-290 allowed in sport?

No. Both are prohibited on the WADA Prohibited List: BPC-157 under S0, and ARA-290 under S0 with an erythropoietin link relevant to S2. [12] [13]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Culver DA et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci 2017PubMed 28475703, 2017
  2. [2]Heij L et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 2012PubMed 23168581, 2012
  3. [3]Brines M et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med 2015PubMed 25387363, 2015
  4. [4]Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell Tissue Res 2019)PubMed 30915550, 2019
  5. [5]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  6. [6]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  7. [7]Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (Curr Pharm Des 2011)PubMed 21548867, 2011
  8. [8]Dahan A et al. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs 2014PubMed 24555851, 2014
  9. [9]Dahan A et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med 2013PubMed 24136731, 2013
  10. [10]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (J Appl Physiol 2011)PubMed 21030672, 2011

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). BPC-157 vs ARA-290 (cibinetide): evidence, cost, and legality. https://peptideagent.ai/compare/bpc-157-vs-ara-290
HTML link
<a href="https://peptideagent.ai/compare/bpc-157-vs-ara-290">BPC-157 vs ARA-290 (cibinetide): evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.